Search company, investor...
Search

Predict your next investment

Ingenza company logo
Corporation
HEALTHCARE | Biotechnology
ingenza.com

See what CB Insights has to offer

Investments

2

Partners & Customers

10

Service Providers

2

About Ingenza

Ingenza, a biocatalyst and bioprocess development company, provides technology to manufacture chiral chemicals and biopharmaceuticals.

Ingenza Headquarters Location

Roslin Innovation Centre, Charnock Bradley Building Easter Bush Campus, Bush Farm Road

Roslin, Scotland, EH25 9RG,

United Kingdom

+44(0)131 651 9681

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Ingenza Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ingenza Rank

Latest Ingenza News

CEPI provides $30m to advance novel coronavirus vaccine

Jul 11, 2022

0 The Coalition for Epidemic Preparedness Innovations (CEPI) has partnered with a consortium of research and technological institutions to fund the development of a novel vaccine to provide protection against COVID-19, as well other SARS-like Betacoronaviruses. The novel coronavirus vaccine has been developed at Caltech and The University of Oxford. Funding of up to $30 million will support vaccine design, its development through Phase I trials and regulatory activities. Manufacturing efforts for the project will be led by the UK’s Centre for Process Innovation (CPI) using microbes engineered by biotechnology Ingenza Ltd. “The creation of vaccines that could provide broad protection against emerging COVID-19 variants and future coronavirus threats would not only help mitigate the damaging effects of another COVID-19-like pandemic, it could also help reduce the time taken and funding spent continually updating vaccine formulations,” commented Dr Richard Hatchett, CEO of the Coalition for Epidemic Preparedness Innovations (CEPI). The novel vaccine, which is based on mosaic‑8 vaccine technology, also has the potential to reduce the costs and supply chain complications associated with production of most vaccines. For example, the new vaccine eliminates the need for cold storage and specialist skills currently concentrated in few nations, increasing its accessibility. “CPI has been working together with these partners since mid-2020 to develop this type of vaccine to ensure it can be manufactured in the quantities and price range required to have a real impact everywhere,” noted Kris Wadrop, CPI General Manager and the Project Lead. “Confirmation of this funding is a testament to the team’s diligence and tenacity to highlight the potential offered by an RBD-nanoparticle vaccine.”  Dr Jack Tan, Senior Postdoctoral Scientist at the MRC Weatherall Institute of Molecular Medicine, University of Oxford, added: ​“We are delighted to be working with CEPI to further this nanoparticle technology with the goal of producing efficacious, low-cost, infrastructure-independent vaccine that will be accessible to low- and middle-income countries.”  How the novel coronavirus vaccine works Many current COVID-19 vaccine candidates work by presenting fragments of the SARS-CoV‑2 spike (S) protein – the receptor-binding domain (RBD) – to the body to generate an immune response. (SARS-CoV‑2 is the virus that causes COVID-19.) The novel vaccine is designed to focus the immune response on parts of RBD shared by all viruses in the Severe Acute Respiratory Syndrome (SARS)-like Betacoronavirus family. It does this by presenting S protein fragment RBDs from SARS-CoV‑2 together with RBDs from seven other different types of coronaviruses on protein nanoparticles termed ​“mosaic‑8” nanoparticles. The mosaic‑8 vaccine approach is being used for development of a novel coronavirus vaccine [Credit: Coalition for Epidemic Preparedness Innovations (CEPI)]. These coronavirus RBDs are attached to a nanoparticle by protein tags, enabling the structure to display fragments from multiple viruses on a single nanoparticle. The innovative protein ​“glue” used as part of the vaccine to attach coronavirus fragments to the nanoparticle was developed from basic science studies of the pathogenic bacterium Streptococcus pyogenes by Professor Mark Howarth at University of Oxford. For manufacturing of the mosaic‑8 vaccine candidate, Ingenza will adapt its Pichia pastoris and Bacillus subtilis manufacturing platforms to prepare each component of this novel vaccine. “We are thrilled to be working with CEPI and our colleagues at Oxford, Ingenza, and CPI to move this vaccine candidate into the clinic,” commented Dr Pamela Bjorkman, the Project Lead and David Baltimore Professor of Biology and Biological Engineering and Merkin Institute Professor at Caltech. “We are very encouraged by pre-clinical results assessing the mosaic RBD nanoparticle approach, which has demonstrated advantages over current vaccines and traditional single RBD nanoparticle vaccine candidates.” The pre-clinical research published in Science demonstrates that the mosaic‑8 nanoparticle vaccine technology elicits protective immune responses against SARS-like Betacoronaviruses with components displayed on the mosaic nanoparticle, as well as coronaviruses from which no components were displayed. This suggests the novel vaccine technology may also provide protection against future SARS-CoV‑2 variants and as-yet-undiscovered coronaviruses that could transfer into the human population. Initial development and validation of the prototype mosaic‑8 vaccine approach was supported by Wellcome Leap and Caltech’s Merkin Institute for Translational Research. Ensuring access to vaccines CEPI is a leader in funding all-in-one coronavirus vaccine research, and to date has made eleven awards under its $200 million programme supporting projects that could provide broad protection against SARS-CoV‑2 variants and other Betacoronaviruses. The programme is part of a $3.5 billion ‘pandemic preparedness plan’ that seeks to reduce/eliminate the threat of future pandemics. In May 2020, CEPI invested  an additional $384 million to accelerate the development and manufacture of Novavax’s NVX-CoV2373 vaccine. Betacoronaviruses are types of coronavirus that cause SARS and Middle East Respiratory Syndrome (MERS), and have been responsible for major epidemics in Asia and the Middle East in recent years. CEPI said it is committed to the principle of equitable access to the vaccines it funds. Under the terms of this agreement, CEPI and its consortium partners – Caltech and The University of Oxford, CPI and Ingenza – have committed to achieving equitable access to the outputs of this project by way of pricing, volume commitments and potential deployment of the technology to low- and middle-income country manufacturers. Related topics

Ingenza Investments

2 Investments

Ingenza has made 2 investments. Their latest investment was in ProFactor Pharma as part of their Unattributed on September 9, 2019.

CBI Logo

Ingenza Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/30/2019

Unattributed

ProFactor Pharma

$2.46M

No

2

8/20/2013

Series A

Subscribe to see more

Subscribe to see more

10

Date

9/30/2019

8/20/2013

Round

Unattributed

Series A

Company

ProFactor Pharma

Subscribe to see more

Amount

$2.46M

New?

No

Subscribe to see more

Co-Investors

Sources

2

10

Ingenza Partners & Customers

10 Partners and customers

Ingenza has 10 strategic partners and customers. Ingenza recently partnered with Johnson Matthey on February 2, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

2/1/2022

Partner

United Kingdom

1

12/4/2018

Licensee

Switzerland

Syngenta exercises licensing option for enabling technology from Ingenza

Our partnership with Ingenza helps us develop innovative crop protection products and the success of the collaboration highlights how well the teams from Syngenta and Ingenza work together ; we look forward to continuing our relationship . ''

1

10/3/2018

Partner

Switzerland

Ingenza announces extension of collaboration with Syngenta

Industrial biotech specialist Ingenza has announced that its collaboration with Syngenta for work on efficient technologies to support the development of crop protection products has been extended .

2

5/31/2018

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

10/18/2017

Partner

Switzerland

Subscribe to see more

Subscribe to see more

10

Date

2/1/2022

12/4/2018

10/3/2018

5/31/2018

10/18/2017

Type

Partner

Licensee

Partner

Partner

Partner

Business Partner

Country

United Kingdom

Switzerland

Switzerland

United Kingdom

Switzerland

News Snippet

Syngenta exercises licensing option for enabling technology from Ingenza

Our partnership with Ingenza helps us develop innovative crop protection products and the success of the collaboration highlights how well the teams from Syngenta and Ingenza work together ; we look forward to continuing our relationship . ''

Ingenza announces extension of collaboration with Syngenta

Industrial biotech specialist Ingenza has announced that its collaboration with Syngenta for work on efficient technologies to support the development of crop protection products has been extended .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

Ingenza Service Providers

2 Service Providers

Ingenza has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Commercial Bank

General Business Banking

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Provider Type

Commercial Bank

Subscribe to see more

Service Type

General Business Banking

Subscribe to see more

Partnership data by VentureSource

Ingenza Team

3 Team Members

Ingenza has 3 team members, including current Founder, Managing Director, Ian Fotheringham.

Name

Work History

Title

Status

Ian Fotheringham

Founder, Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Ian Fotheringham

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Managing Director

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.